eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | hyperthermia |
| Comorbidity | C0027947|neutropenia |
| Sentences | 77 |
| PubMedID- 22661287 | Common terminology criteria of adverse events (ctcae) grade >/= 3 neutropenia (with or without fever) occurred in 34% of patients overall. |
| PubMedID- 22460270 | However,the first two patients had grade 4 neutropenia with febrile episode. |
| PubMedID- 20351213 | We conclude that brrna rt-qpcr could be useful in the diagnosis of fever with neutropenia, given its high bacterial detection rate, short turnaround time, and the small blood sample required compared with the standard blood culture techniques. |
| PubMedID- 25409861 | neutropenia with or without fever is a relevant cause of morbidity, mortality and costs, compromising treatment administration and clinical outcomes. |
| PubMedID- 24551455 | Among grade 4 events, 2 neutropenia events of which 1 of febrile neutropenia, and 2 leukopenia events occurred. |
| PubMedID- 22843906 | The observed side-effects were as expected, with grade 3-4 neutropenia developing in 38% of the cycles, whereas febrile neutropenia occurred in only 12% of the patients. |
| PubMedID- 21747881 | neutropenia with fever and uncontrolled severe infection were complications in 87% and 27% of the patients, respectively. |
| PubMedID- 25961061 | The maximal tolerated dose (mtd) for daily iv infusions was 30 μg/kg, and dose-limiting toxicities consisted of hepatotoxicity, neutropenia, and lightheadedness with fever and rigors. |
| PubMedID- 24198852 | If neutropenia with pyrexia >38.0º c is present, blood cultures and samples from other sites should be sent for microbiological examination. |
| PubMedID- 23304129 | About 45% of patients experienced grade 3/4 neutropenia, including febrile neutropenia in 5.4%. |
| PubMedID- 25444524 | Study design: episodes of fever without neutropenia (absolute neutrophil count [anc] >/=500 cells/mm(3)) were reviewed retrospectively in pediatric oncology patients with a cvc undergoing chemotherapy. |
| PubMedID- 21610706 | Dose-limiting toxicity was defined as one of the following adverse events (aes) occurring during cycle 1: grade 4 haematological toxicity; grade 3 neutropenia with infection or fever ⩾38.5°c; grade ⩾3 non-haematological treatment-related toxicity, except toxicities which had not been maximally treated (such as nausea, vomiting and diarrhoea) or that the patient considered tolerable (such as skin rash); confirmed grade 3 qtc prolongation (qtc >500 ms) persisting after correction of other possible causes such as electrolyte imbalance or hypoxia; or inability to receive the next dose of pd 0332991 within 1 week (±1 day) of the last dose because of lack of haematological recovery or prolonged non-haematological toxicity grade ⩾3. |
| PubMedID- 21265012 | Procedure: we performed a retrospective review of all oncology patients admitted to the hospital from january 2004 through december 2008 for fn who had daily fevers with neutropenia for 4 or more consecutive days prompting ct evaluation. |
| PubMedID- 21792316 | The most common grade ≥3 toxicity was neutropenia (75%) with 11% febrile neutropenia. |
| PubMedID- 22479278 | Dlts were defined as grade 4 neutropenia associated with fever for more than 3 days; grade 4 neutropenia lasting for more than 10 days; grade 3-4 thrombocytopenia with grade 2 hemorrhage; or grade 3-4 non-hematologic toxicity during the first treatment cycle. |
| PubMedID- 22215473 | Grade 3 or 4 neutropenia occurred in 35.3% of patients, and febrile neutropenia occurred in only 3 (3.5%) patients. |
| PubMedID- 25171229 | Toxicities were as follows (safety population): 21.6% severe leukopenia, 9.1% severe neutropenia (with 1 febrile neutropenia), 1 case of bowel perforation, 36% diarrhea (3% severe), 84.8% nausea (severe 15.2%), 48.5% vomiting (severe 9.1%), 27.3% infections (severe 6.1%), 12.1% peripheral neuropathy (severe 9.1%), and 36.4% dyspnea (3% severe). |
| PubMedID- 23975510 | One of 6 patients at dose level 2 (5 mg everolimus) had grade 3 hepatotoxicity and 3 of 6 patients at level 3 (7.5 mg everolimus) had grade 4 hematologic toxicities (two grade 4 thrombocytopenia and one grade 4 neutropenia with fever lasting more than 3 days). |
| PubMedID- 22050689 | Mbl2 and fever during neutropenia in children with acute lymphoblastic leukaemia. |
| PubMedID- 24761216 | The therapeutic administration of csfs in afebrile patients with neutropenia might lower the rate of febrile neutropenia; however, considering that csfs for the treatment of febrile neutropenia do not reduce the risk of death, their cost, and their adverse events, administration of csfs in patients with afebrile neutropenia should be limited. |
| PubMedID- 23255844 | In addition, low cd4 cell counts and high-risk chemotherapeutic regimens for severe neutropenia were associated with febrile illness with prolonged neutropenia. |
| PubMedID- 23095790 | The predominant toxicity was grade 3-4 neutropenia, occurring in 92% of the patients, although febrile neutropenia arose in 10% of the patients. |
| PubMedID- 25345994 | fever and fever with neutropenia (fn) were the two most common diagnoses, accounting for almost 20% of visits. |
| PubMedID- 25931813 | If an adverse event required dose interruption, the nab-paclitaxel dose was reinitiated at the start of a treatment cycle if the patient’s absolute neutrophil count was ≥ 1,500 cells/µl, the patient's platelet count was ≥ 100,000 cells/µl, and any other toxicity resolved to grade 1. patients experiencing grade 3–4 neutropenia, with or without fever, or grade 2 symptomatic anemia could receive hematological support with granulocyte colony-stimulating factor or erythropoietin. |
| PubMedID- 23406736 | Only grade 3/4 toxicity was hematologic: neutropenia (3.1% of cycles), febrile neutropenia (0.2%), and anemia (0.2%). |
| PubMedID- 25674158 | Sixty-eight months after transplant the patient presented febrile with neutropenia and thrombocytopenia, bone marrow aspirates showed 98% of blasts consistent with aml m1 (figure 1a-b), which was compatible with the immunophenotype.figure 1bone marrow aspirates. |
| PubMedID- 22790797 | Haematologic dlts were grade 3/4 neutropenia complicated by fever ⩾38.5 °c or infection, grade 4 neutropenia for ⩾7 days, grade 4 thrombocytopenia, or grade 3 thrombocytopenia with haemorrhage. |
| PubMedID- 21373895 | Dose-limiting toxicity (dlt) during cycle 1 included: (1) neutrophil nadir < 500/mul attributed to therapy, (2) platelet nadir < 50,000/mul attributed to therapy, (3) grade 3-4 non-hematologic toxicity attributed to therapy, and (4) neutropenia associated with grade 2 fever (i.e., febrile neutropenia). |
| PubMedID- 21831476 | Overall nci-ctc grade 3 and 4 toxicity was mainly hematological: neutropenia (71% of the patients, febrile neutropenia 9.4% of the cycles), thrombocytopenia (23%), and anemia (22%). |
| PubMedID- 25395866 | neutropenia, duration of neutropenia, fever, duration of fever, and c-reactive protein (crp) were evaluated throughout the study. |
| PubMedID- 20878160 | One patient had grade 3 neutropenia lasting 5 days with fever, 1 had grade 3 anemia, 1 experienced grade 2 nausea, two experienced grade 2 anorexia, one had grade 1 mucositis, and one patient experienced grade 2 sensory neuropathy. |
| PubMedID- 23963141 | None of the six patients entered at dose level 1 experienced dlt in cycle 1, allowing escalation to dose level 2. at dose level 2, one out of the six patients experienced dlt (fever with grade 4 neutropenia and grade 3 thrombocytopenia, leading to death) in cycle 1, allowing escalation to dose level 3. at dose level 3, the first (grade 4 thrombocytopenia) and the third (grade 3 hyperglycemia) patients experienced dlts during cycle 1; thus, level 2 was regarded as the highest well-tolerated dose and this cohort was expanded by an additional six patients to obtain additional safety and pharmacokinetic data. |
| PubMedID- 23179335 | A dlt was defined as any of the following toxicities occurring during the first 2 cycles (cycles 1 and 2): grade 3 or 4 neutropenia complicated by fever (≥38.5 °c) or infection; grade 4 neutropenia persisting for >7 days; grade 4 thrombocytopenia or grade 3 thrombocytopenia complicated by hemorrhage; grade 4 non-hematologic toxicities; grade 3 non-hematologic toxicities other than fatigue, anorexia, nausea, vomiting, or hyponatremia; uncontrolled hypertension or proteinuria; and symptomatic arterial thromboembolic events. |
| PubMedID- 25943747 | Granulocyte colony-stimulating factors were allowed in grade 3 neutropenia with fever lasting ≥3 days or in case of grade 4 neutropenia. |
| PubMedID- 23943780 | neutropenia in patients with shanghai fever was probably induced by p aeruginosa infection rather than a predisposing factor for the infection. |
| PubMedID- 25671574 | Virtually applying different tldfs, the number of episodes of fever (with or without neutropenia) increased from 124 at limitstandard to 291 (235%) at 38.5°c, to 604 (487%) at 38.0°c, and to 1191 (960%) at 37.5°c. |
| PubMedID- 25684313 | Treatment had to be stopped early in eight (19%) patients, mainly due to limiting toxicity in five patients (diarrhea, febrile neutropenia, neutropenia without fever, diarrhea with febrile neutropenia, and skin toxicity), one toxic death (colonic perforation), one acute pancreatitis, and one consent withdrawal. |
| PubMedID- 24455636 | Background: neutropenia with fever is a common syndrome in patients with hematologic malignancies who have a high risk of infectious diseases. |
| PubMedID- 26376233 | Current guidelines encourage empiric antibiotics in febrile patients with chemotherapy-induced neutropenia to reduce infection-related mortalities. |
| PubMedID- 22395759 | Purpose of review: fever in neutropenia is the most frequent potentially life-threatening complication of chemotherapy in children and adolescents with cancer. |
| PubMedID- 23338051 | Grade 4 neutropenia developed in 53.5% of patients and febrile neutropenia in 16.3%. |
| PubMedID- 24434034 | neutropenia with fever (febrile neutropenia [fn]) is a serious consequence of myelosuppressive chemotherapy that usually results in hospitalization and the need for intravenous antibiotics. |
| PubMedID- 20579327 | neutropenia with fever occurred in 8% of dogs after treatment with vinblastine and in 2% after treatment with ccnu. |
| PubMedID- 21209804 | The combined regimen just caused grade-4 neutropenia associated with febrile episode in one patient and grade-one peripheral sensory neuropathy in three patients, which indicated a good tolerance. |
| PubMedID- 21285987 | Dlts were defined as grade 4 neutropenia associated with fever (⩾38.5°c) or diarrhoea ⩾ grade 2, grade 4 neutropenia lasting ⩾5 days without fever, grade 4 thrombocytopenia for ⩾5 days, grade 3 or higher non-haematological toxicity (except liver transaminase elevation, or nausea or vomiting treatable by anti-emetic), and treatment delay >2 weeks before start of next cycle of treatment because of unresolved toxicity. |
| PubMedID- 20564143 | The dose-limiting toxicities (dlts) were fever with grade 3/4 neutropenia, grade 3 fatigue, and grade 3 mucositis. |
| PubMedID- 22237937 | The incidence of neutropenia and infection with febrile neutropenia were higher in the mpt subgroup with low gfr than the others (p = 0.016, p < 0.001). |
| PubMedID- 21540759 | fever with severe neutropenia was more common in patients with lrti than with urti (p = 0.02). |
| PubMedID- 23228190 | Dose limiting toxicity (dlt) was defined as grade 3 neutropenia with fever or infection; grade 4 neutropenia persisting ≥ 7 days; grade 3 thrombocytopenia with bleeding or grade 4 thrombocytopenia > 7 days; any non-hematological toxicity grade 3 or 4 except alopecia, nausea and vomiting; increase in urinary retention parameters ≥ grade 2; peripheral sensory neuropathy ≥ grade 3. relation between study drug and toxicity was evaluated with respect to the differences of the side effects of fluoruracil/leucovorin and capecitabine. |
| PubMedID- 23408310 | Transient neutropenia in children with febrile illness and associated infectious agents: 2 years' follow-up. |
Page: 1 2